Cubist Pharmaceuticals, Inc. (CBST)

[surf1944]

7:08AM Cubist Pharma announces FY09 total net revenue of $562.1 mln vs $559.5 consensus (CBST) 18.78 : Co announces 4Q09 U.S. CUBICIN net product revenues of $147.8 mln (unaudited); this represents an increase of 23%, or $27.7 mln, from 4Q08 U.S. CUBICIN net product revenues. Co announces FY09 U.S. CUBICIN net product revenues of $524.0 mln (unaudited); this represents an increase of 26%, or $109.3 mln, from FY08 U.S. CUBICIN net product revenues. Co's share of FY09 international net product revenues was $13.8 mln (unaudited); this represents an increase of 86%, or $6.4 mln, from FY08. Service revenues for FY09 were $22.5 mln (unaudited), an increase of 139%, or $13.1 mln, from 2008 and relate to Cubist's promotion and other activities in the U.S. with respect to MERREM I.V. Total net revenue for FY09 was $562.1 mln vs $559.5 mln consensus.